Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

Determining the incidence of familiality in ALS: A study of temporal trends in Ireland from 1994 to 2016.

Ryan M, Heverin M, Doherty MA, Davis N, Corr EM, Vajda A, Pender N, McLaughlin R, Hardiman O.

Neurol Genet. 2018 May 18;4(3):e239. doi: 10.1212/NXG.0000000000000239. eCollection 2018 Jun.

2.

The Study of Language in the Amyotrophic Lateral Sclerosis - Frontotemporal Spectrum Disorder: a Systematic Review of Findings and New Perspectives.

Pinto-Grau M, Hardiman O, Pender N.

Neuropsychol Rev. 2018 Jun;28(2):251-268. doi: 10.1007/s11065-018-9375-7. Epub 2018 Apr 28. Review.

PMID:
29705950
3.

Multicentre, cross-cultural, population-based, case-control study of physical activity as risk factor for amyotrophic lateral sclerosis.

Visser AE, Rooney JPK, D'Ovidio F, Westeneng HJ, Vermeulen RCH, Beghi E, Chiò A, Logroscino G, Hardiman O, Veldink JH, van den Berg LH; Euro-MOTOR consortium.

J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):797-803. doi: 10.1136/jnnp-2017-317724. Epub 2018 Apr 23.

PMID:
29685899
4.

Understanding the use of NIV in ALS: results of an international ALS specialist survey.

Heiman-Patterson TD, Cudkowicz ME, De Carvalho M, Genge A, Hardiman O, Jackson CE, Lechtzin N, Mitsumoto H, Silani V, Andrews JA, Chen D, Kulke S, Rudnicki SA, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):331-341. doi: 10.1080/21678421.2018.1457058. Epub 2018 Apr 16.

PMID:
29661084
5.

Referral bias in ALS epidemiological studies.

Logroscino G, Marin B, Piccininni M, Arcuti S, Chiò A, Hardiman O, Rooney J, Zoccolella S, Couratier P, Preux PM, Beghi E; for EURALS.

PLoS One. 2018 Apr 16;13(4):e0195821. doi: 10.1371/journal.pone.0195821. eCollection 2018.

6.

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.

Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, Körner S, Ringer TM, Rödiger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chiò A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH.

Lancet Neurol. 2018 May;17(5):423-433. doi: 10.1016/S1474-4422(18)30089-9. Epub 2018 Mar 26.

7.

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, Rivera AM, van Rheenen W, Murphy NA, van Vugt JJFA, Geiger JT, Van der Spek RA, Pliner HA, Shankaracharya, Smith BN, Marangi G, Topp SD, Abramzon Y, Gkazi AS, Eicher JD, Kenna A; ITALSGEN Consortium, Mora G, Calvo A, Mazzini L, Riva N, Mandrioli J, Caponnetto C, Battistini S, Volanti P, La Bella V, Conforti FL, Borghero G, Messina S, Simone IL, Trojsi F, Salvi F, Logullo FO, D'Alfonso S, Corrado L, Capasso M, Ferrucci L; Genomic Translation for ALS Care (GTAC) Consortium, Moreno CAM, Kamalakaran S, Goldstein DB; ALS Sequencing Consortium, Gitler AD, Harris T, Myers RM; NYGC ALS Consortium, Phatnani H, Musunuri RL, Evani US, Abhyankar A, Zody MC; Answer ALS Foundation, Kaye J, Finkbeiner S, Wyman SK, LeNail A, Lima L, Fraenkel E, Svendsen CN, Thompson LM, Van Eyk JE, Berry JD, Miller TM, Kolb SJ, Cudkowicz M, Baxi E; Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Benatar M, Taylor JP, Rampersaud E, Wu G, Wuu J; SLAGEN Consortium, Lauria G, Verde F, Fogh I, Tiloca C, Comi GP, Sorarù G, Cereda C; French ALS Consortium, Corcia P, Laaksovirta H, Myllykangas L, Jansson L, Valori M, Ealing J, Hamdalla H, Rollinson S, Pickering-Brown S, Orrell RW, Sidle KC, Malaspina A, Hardy J, Singleton AB, Johnson JO, Arepalli S, Sapp PC, McKenna-Yasek D, Polak M, Asress S, Al-Sarraj S, King A, Troakes C, Vance C, de Belleroche J, Baas F, Ten Asbroek ALMA, Muñoz-Blanco JL, Hernandez DG, Ding J, Gibbs JR, Scholz SW, Floeter MK, Campbell RH, Landi F, Bowser R, Pulst SM, Ravits JM, MacGowan DJL, Kirby J, Pioro EP, Pamphlett R, Broach J, Gerhard G, Dunckley TL, Brady CB, Kowall NW, Troncoso JC, Le Ber I, Mouzat K, Lumbroso S, Heiman-Patterson TD, Kamel F, Van Den Bosch L, Baloh RH, Strom TM, Meitinger T, Shatunov A, Van Eijk KR, de Carvalho M, Kooyman M, Middelkoop B, Moisse M, McLaughlin RL, Van Es MA, Weber M, Boylan KB, Van Blitterswijk M, Rademakers R, Morrison KE, Basak AN, Mora JS, Drory VE, Shaw PJ, Turner MR, Talbot K, Hardiman O, Williams KL, Fifita JA, Nicholson GA, Blair IP, Rouleau GA, Esteban-Pérez J, García-Redondo A, Al-Chalabi A; Project MinE ALS Sequencing Consortium, Rogaeva E, Zinman L, Ostrow LW, Maragakis NJ, Rothstein JD, Simmons Z, Cooper-Knock J, Brice A, Goutman SA, Feldman EL, Gibson SB, Taroni F, Ratti A, Gellera C, Van Damme P, Robberecht W, Fratta P, Sabatelli M, Lunetta C, Ludolph AC, Andersen PM, Weishaupt JH, Camu W, Trojanowski JQ, Van Deerlin VM, Brown RH Jr, van den Berg LH, Veldink JH, Harms MB, Glass JD, Stone DJ, Tienari P, Silani V, Chiò A, Shaw CE, Traynor BJ, Landers JE.

Neuron. 2018 Mar 21;97(6):1268-1283.e6. doi: 10.1016/j.neuron.2018.02.027.

PMID:
29566793
8.

Respiratory measures in amyotrophic lateral sclerosis.

Lechtzin N, Cudkowicz ME, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, Mora JS, Shefner J, Van den Berg LH, Andrews JA.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):321-330. doi: 10.1080/21678421.2018.1452945. Epub 2018 Mar 23. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):478.

PMID:
29566571
9.

Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study.

Bede P, Omer T, Finegan E, Chipika RH, Iyer PM, Doherty MA, Vajda A, Pender N, McLaughlin RL, Hutchinson S, Hardiman O.

Brain Imaging Behav. 2018 Feb 8. doi: 10.1007/s11682-018-9837-9. [Epub ahead of print]

PMID:
29423814
10.

VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.

Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):259-266. doi: 10.1080/21678421.2018.1426770. Epub 2018 Feb 6. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):321.

PMID:
29402141
11.

Longitudinal predictors of caregiver burden in amyotrophic lateral sclerosis: a population-based cohort of patient-caregiver dyads.

Burke T, Hardiman O, Pinto-Grau M, Lonergan K, Heverin M, Tobin K, Staines A, Galvin M, Pender N.

J Neurol. 2018 Apr;265(4):793-808. doi: 10.1007/s00415-018-8770-6. Epub 2018 Feb 2.

PMID:
29396678
12.

Needs of informal caregivers across the caregiving course in amyotrophic lateral sclerosis: a qualitative analysis.

Galvin M, Carney S, Corr B, Mays I, Pender N, Hardiman O.

BMJ Open. 2018 Jan 27;8(1):e018721. doi: 10.1136/bmjopen-2017-018721.

13.

Insular Celtic population structure and genomic footprints of migration.

Byrne RP, Martiniano R, Cassidy LM, Carrigan M, Hellenthal G, Hardiman O, Bradley DG, McLaughlin RL.

PLoS Genet. 2018 Jan 25;14(1):e1007152. doi: 10.1371/journal.pgen.1007152. eCollection 2018 Jan.

14.

Reconsidering the causality of TIA1 mutations in ALS.

van der Spek RA, van Rheenen W, Pulit SL, Kenna KP, Ticozzi N, Kooyman M, Mclaughlin RL, Moisse M, van Eijk KR, van Vugt JJFA, Iacoangeli A, Andersen P, Nazli Basak A, Blair I, de Carvalho M, Chio A, Corcia P, Couratier P, Drory VE, Glass JD, Hardiman O, Mora JS, Morrison KE, Mitne-Neto M, Robberecht W, Shaw PJ, Panadés MP, van Damme P, Silani V, Gotkine M, Weber M, van Es MA, Landers JE, Al-Chalabi A, van den Berg LH, Veldink JH; PROJECT MINE ALS SEQUENCING CONSORTIUM.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):1-3. doi: 10.1080/21678421.2017.1413118. Epub 2017 Dec 13. No abstract available. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):161.

PMID:
29235362
15.

Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration.

Bede P, Hardiman O.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):232-241. doi: 10.1080/21678421.2017.1407795. Epub 2017 Dec 7.

PMID:
29214883
16.

Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS).

Crockford C, Newton J, Lonergan K, Madden C, Mays I, O'Sullivan M, Costello E, Pinto-Grau M, Vajda A, Heverin M, Pender N, Al-Chalabi A, Hardiman O, Abrahams S.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):65-73. doi: 10.1080/21678421.2017.1407794. Epub 2017 Dec 7.

PMID:
29214872
17.

ECAS A-B-C: alternate forms of the Edinburgh Cognitive and Behavioural ALS Screen.

Crockford CJ, Kleynhans M, Wilton E, Radakovic R, Newton J, Niven EH, Al-Chalabi A, Hardiman O, Bak TH, Abrahams S.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):57-64. doi: 10.1080/21678421.2017.1407793. Epub 2017 Dec 5.

PMID:
29205065
18.

Characteristic Increases in EEG Connectivity Correlate With Changes of Structural MRI in Amyotrophic Lateral Sclerosis.

Nasseroleslami B, Dukic S, Broderick M, Mohr K, Schuster C, Gavin B, McLaughlin R, Heverin M, Vajda A, Iyer PM, Pender N, Bede P, Lalor EC, Hardiman O.

Cereb Cortex. 2017 Nov 9:1-15. doi: 10.1093/cercor/bhx301. [Epub ahead of print]

PMID:
29136131
19.

Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium.

Pupillo E, Poloni M, Bianchi E, Giussani G, Logroscino G, Zoccolella S, Chiò A, Calvo A, Corbo M, Lunetta C, Marin B, Mitchell D, Hardiman O, Rooney J, Stevic Z, Bandettini di Poggio M, Filosto M, Cotelli MS, Perini M, Riva N, Tremolizzo L, Vitelli E, Damiani D, Beghi E; EURALS Consortium†.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):118-125. doi: 10.1080/21678421.2017.1386687. Epub 2017 Oct 24.

PMID:
29063790
20.

Estimation of coherence using the median is robust against EEG artefacts.

Dukic S, Iyer PM, Mohr K, Hardiman O, Lalor EC, Nasseroleslami B.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:3949-3952. doi: 10.1109/EMBC.2017.8037720.

PMID:
29060761
21.

Amyotrophic lateral sclerosis.

Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH.

Nat Rev Dis Primers. 2017 Oct 20;3:17085. doi: 10.1038/nrdp.2017.85.

PMID:
29052611
22.

Clustering of Neuropsychiatric Disease in First-Degree and Second-Degree Relatives of Patients With Amyotrophic Lateral Sclerosis.

O'Brien M, Burke T, Heverin M, Vajda A, McLaughlin R, Gibbons J, Byrne S, Pinto-Grau M, Elamin M, Pender N, Hardiman O.

JAMA Neurol. 2017 Dec 1;74(12):1425-1430. doi: 10.1001/jamaneurol.2017.2699.

PMID:
29049464
23.

Amyotrophic lateral sclerosis.

Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH.

Nat Rev Dis Primers. 2017 Oct 5;3:17071. doi: 10.1038/nrdp.2017.71. Review. Erratum in: Nat Rev Dis Primers. 2017 Oct 20;3:17085.

PMID:
28980624
24.

The beginning of precision medicine in ALS? Treatment to fit the genes.

Armon C, Hardiman O.

Neurology. 2017 Oct 31;89(18):1850-1851. doi: 10.1212/WNL.0000000000004612. Epub 2017 Oct 4. No abstract available.

PMID:
28978653
25.

July 2017 ENCALS statement on edaravone.

Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M, Desnuelle C, Grehl T, Grosskreutz J, Holmøy T, Ingre C, Karlsborg M, Kleveland G, Koch JC, Koritnik B, KuzmaKozakiewicz M, Laaksovirta H, Ludolph A, McDermott C, Meyer T, Mitre Ropero B, Mora Pardina J, Nygren I, Petri S, Povedano Panades M, Salachas F, Shaw P, Silani V, Staaf G, Svenstrup K, Talbot K, Tysnes OB, Van Damme P, van der Kooi A, Weber M, Weydt P, Wolf J, Hardiman O, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):471-474. doi: 10.1080/21678421.2017.1369125. Epub 2017 Oct 4. No abstract available.

PMID:
28975816
26.

Detection of long repeat expansions from PCR-free whole-genome sequence data.

Dolzhenko E, van Vugt JJFA, Shaw RJ, Bekritsky MA, van Blitterswijk M, Narzisi G, Ajay SS, Rajan V, Lajoie BR, Johnson NH, Kingsbury Z, Humphray SJ, Schellevis RD, Brands WJ, Baker M, Rademakers R, Kooyman M, Tazelaar GHP, van Es MA, McLaughlin R, Sproviero W, Shatunov A, Jones A, Al Khleifat A, Pittman A, Morgan S, Hardiman O, Al-Chalabi A, Shaw C, Smith B, Neo EJ, Morrison K, Shaw PJ, Reeves C, Winterkorn L, Wexler NS; US–Venezuela Collaborative Research Group, Housman DE, Ng CW, Li AL, Taft RJ, van den Berg LH, Bentley DR, Veldink JH, Eberle MA.

Genome Res. 2017 Nov;27(11):1895-1903. doi: 10.1101/gr.225672.117. Epub 2017 Sep 8.

27.

Mismatch Negativity as an Indicator of Cognitive Sub-Domain Dysfunction in Amyotrophic Lateral Sclerosis.

Iyer PM, Mohr K, Broderick M, Gavin B, Burke T, Bede P, Pinto-Grau M, Pender NP, McLaughlin R, Vajda A, Heverin M, Lalor EC, Hardiman O, Nasseroleslami B.

Front Neurol. 2017 Aug 15;8:395. doi: 10.3389/fneur.2017.00395. eCollection 2017.

28.

Cerebral venous sinus thrombosis in homocystinuria: Dietary intervention in conjunction with anticoagulation.

Yap S, Annesley-Williams D, Hardiman O.

SAGE Open Med Case Rep. 2017 Aug 1;5:2050313X17722289. doi: 10.1177/2050313X17722289. eCollection 2017.

29.

A case-control study of hormonal exposures as etiologic factors for ALS in women: Euro-MOTOR.

Rooney JPK, Visser AE, D'Ovidio F, Vermeulen R, Beghi E, Chio A, Veldink JH, Logroscino G, van den Berg LH, Hardiman O; Euro-MOTOR Consortium.

Neurology. 2017 Sep 19;89(12):1283-1290. doi: 10.1212/WNL.0000000000004390. Epub 2017 Aug 23.

PMID:
28835399
30.

Virtual brain biopsies in amyotrophic lateral sclerosis: Diagnostic classification based on in vivo pathological patterns.

Bede P, Iyer PM, Finegan E, Omer T, Hardiman O.

Neuroimage Clin. 2017 Jun 9;15:653-658. doi: 10.1016/j.nicl.2017.06.010. eCollection 2017.

31.

Genetic screening in sporadic ALS and FTD.

Turner MR, Al-Chalabi A, Chio A, Hardiman O, Kiernan MC, Rohrer JD, Rowe J, Seeley W, Talbot K.

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1042-1044. doi: 10.1136/jnnp-2017-315995. Epub 2017 Jun 22.

32.

The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: A population- based study of consultations, interventions and costs.

Galvin M, Ryan P, Maguire S, Heverin M, Madden C, Vajda A, Normand C, Hardiman O.

PLoS One. 2017 Jun 22;12(6):e0179796. doi: 10.1371/journal.pone.0179796. eCollection 2017.

33.

Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms.

Madill M, McDonagh K, Ma J, Vajda A, McLoughlin P, O'Brien T, Hardiman O, Shen S.

Mol Brain. 2017 Jun 13;10(1):22. doi: 10.1186/s13041-017-0300-4.

34.

Assessing behavioural changes in ALS: cross-validation of ALS-specific measures.

Pinto-Grau M, Costello E, O'Connor S, Elamin M, Burke T, Heverin M, Pender N, Hardiman O.

J Neurol. 2017 Jul;264(7):1397-1401. doi: 10.1007/s00415-017-8536-6. Epub 2017 Jun 9.

PMID:
28600595
35.

Critical issues in ALS case-control studies: the case of the Euro-MOTOR study.

D'Ovidio F, Rooney JPK, Visser AE, Vermeulen RCH, Veldink JH, Van Den Berg LH, Hardiman O, Logroscino G, Chiò A, Beghi E; Euro-MOTOR Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Aug;18(5-6):411-418. doi: 10.1080/21678421.2017.1285939. Epub 2017 Feb 10.

PMID:
28594593
36.

Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study.

Omer T, Finegan E, Hutchinson S, Doherty M, Vajda A, McLaughlin RL, Pender N, Hardiman O, Bede P.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):611-623. doi: 10.1080/21678421.2017.1332077. Epub 2017 May 31.

PMID:
28562080
37.

Amyotrophic lateral sclerosis.

van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH.

Lancet. 2017 Nov 4;390(10107):2084-2098. doi: 10.1016/S0140-6736(17)31287-4. Epub 2017 May 25. Review.

PMID:
28552366
38.

Edaravone: a new treatment for ALS on the horizon?

Hardiman O, van den Berg LH.

Lancet Neurol. 2017 Jul;16(7):490-491. doi: 10.1016/S1474-4422(17)30163-1. Epub 2017 May 15. No abstract available.

PMID:
28522180
39.

Benefits, pitfalls, and future design of population-based registers in neurodegenerative disease.

Rooney JPK, Brayne C, Tobin K, Logroscino G, Glymour MM, Hardiman O.

Neurology. 2017 Jun 13;88(24):2321-2329. doi: 10.1212/WNL.0000000000004038. Epub 2017 May 17. Review.

PMID:
28515268
40.

A Cross-sectional population-based investigation into behavioral change in amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival.

Burke T, Pinto-Grau M, Lonergan K, Bede P, O'Sullivan M, Heverin M, Vajda A, McLaughlin RL, Pender N, Hardiman O.

Ann Clin Transl Neurol. 2017 Apr 11;4(5):305-317. doi: 10.1002/acn3.407. eCollection 2017 May.

41.

Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis.

Smith BN, Topp SD, Fallini C, Shibata H, Chen HJ, Troakes C, King A, Ticozzi N, Kenna KP, Soragia-Gkazi A, Miller JW, Sato A, Dias DM, Jeon M, Vance C, Wong CH, de Majo M, Kattuah W, Mitchell JC, Scotter EL, Parkin NW, Sapp PC, Nolan M, Nestor PJ, Simpson M, Weale M, Lek M, Baas F, Vianney de Jong JM, Ten Asbroek ALMA, Redondo AG, Esteban-Pérez J, Tiloca C, Verde F, Duga S, Leigh N, Pall H, Morrison KE, Al-Chalabi A, Shaw PJ, Kirby J, Turner MR, Talbot K, Hardiman O, Glass JD, De Belleroche J, Maki M, Moss SE, Miller C, Gellera C, Ratti A, Al-Sarraj S, Brown RH Jr, Silani V, Landers JE, Shaw CE.

Sci Transl Med. 2017 May 3;9(388). pii: eaad9157. doi: 10.1126/scitranslmed.aad9157.

42.

Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics.

Schuster C, Hardiman O, Bede P.

BMC Neurol. 2017 Apr 17;17(1):73. doi: 10.1186/s12883-017-0854-x.

43.

Genetic effects influencing risk for major depressive disorder in China and Europe.

Bigdeli TB, Ripke S, Peterson RE, Trzaskowski M, Bacanu SA, Abdellaoui A, Andlauer TF, Beekman AT, Berger K, Blackwood DH, Boomsma DI, Breen G, Buttenschøn HN, Byrne EM, Cichon S, Clarke TK, Couvy-Duchesne B, Craddock N, de Geus EJ, Degenhardt F, Dunn EC, Edwards AC, Fanous AH, Forstner AJ, Frank J, Gill M, Gordon SD, Grabe HJ, Hamilton SP, Hardiman O, Hayward C, Heath AC, Henders AK, Herms S, Hickie IB, Hoffmann P, Homuth G, Hottenga JJ, Ising M, Jansen R, Kloiber S, Knowles JA, Lang M, Li QS, Lucae S, MacIntyre DJ, Madden PA, Martin NG, McGrath PJ, McGuffin P, McIntosh AM, Medland SE, Mehta D, Middeldorp CM, Milaneschi Y, Montgomery GW, Mors O, Müller-Myhsok B, Nauck M, Nyholt DR, Nöthen MM, Owen MJ, Penninx BW, Pergadia ML, Perlis RH, Peyrot WJ, Porteous DJ, Potash JB, Rice JP, Rietschel M, Riley BP, Rivera M, Schoevers R, Schulze TG, Shi J, Shyn SI, Smit JH, Smoller JW, Streit F, Strohmaier J, Teumer A, Treutlein J, Van der Auwera S, van Grootheest G, van Hemert AM, Völzke H, Webb BT, Weissman MM, Wellmann J, Willemsen G, Witt SH, Levinson DF, Lewis CM, Wray NR, Flint J, Sullivan PF, Kendler KS.

Transl Psychiatry. 2017 Mar 28;7(3):e1074. doi: 10.1038/tp.2016.292.

44.

Genetic correlation between amyotrophic lateral sclerosis and schizophrenia.

McLaughlin RL, Schijven D, van Rheenen W, van Eijk KR, O'Brien M, Kahn RS, Ophoff RA, Goris A, Bradley DG, Al-Chalabi A, van den Berg LH, Luykx JJ, Hardiman O, Veldink JH; Project MinE GWAS Consortium; Schizophrenia Working Group of the Psychiatric Genomics Consortium.

Nat Commun. 2017 Mar 21;8:14774. doi: 10.1038/ncomms14774.

45.

From first symptoms to diagnosis of amyotrophic lateral sclerosis: perspectives of an Irish informal caregiver cohort-a thematic analysis.

Galvin M, Gaffney R, Corr B, Mays I, Hardiman O.

BMJ Open. 2017 Mar 20;7(3):e014985. doi: 10.1136/bmjopen-2016-014985.

46.

The changing picture of amyotrophic lateral sclerosis: lessons from European registers.

Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, Martin S, Logroscino G, Rooney J.

J Neurol Neurosurg Psychiatry. 2017 Jul;88(7):557-563. doi: 10.1136/jnnp-2016-314495. Epub 2017 Mar 11. Review.

47.

Caregivers of patients with amyotrophic lateral sclerosis: investigating quality of life, caregiver burden, service engagement, and patient survival.

Burke T, Galvin M, Pinto-Grau M, Lonergan K, Madden C, Mays I, Carney S, Hardiman O, Pender N.

J Neurol. 2017 May;264(5):898-904. doi: 10.1007/s00415-017-8448-5. Epub 2017 Mar 9.

PMID:
28280986
48.

Genetic testing in ALS: A survey of current practices.

Vajda A, McLaughlin RL, Heverin M, Thorpe O, Abrahams S, Al-Chalabi A, Hardiman O.

Neurology. 2017 Mar 7;88(10):991-999. doi: 10.1212/WNL.0000000000003686. Epub 2017 Feb 3. Review.

49.

Visual encoding, consolidation, and retrieval in amyotrophic lateral sclerosis: executive function as a mediator, and predictor of performance.

Burke T, Lonergan K, Pinto-Grau M, Elamin M, Bede P, Madden C, Hardiman O, Pender N.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):193-201. doi: 10.1080/21678421.2016.1272615. Epub 2017 Jan 13.

PMID:
28084080
50.

A genetic overview of Atlantic coastal populations from Europe and North-West Africa based on a 17 X-STR panel.

Prieto-Fernández E, Díaz-de Usera A, Baeta M, Núñez C, Chbel F, Nadifi S, Rouault K, Férec C, Hardiman O, Pinheiro F, de Pancorbo MM.

Forensic Sci Int Genet. 2017 Mar;27:167-171. doi: 10.1016/j.fsigen.2016.11.011. Epub 2016 Nov 30.

PMID:
27931869

Supplemental Content

Loading ...
Support Center